These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 1812426)

  • 21. Serum opsonins to serogroup B meningococci after disease and vaccination.
    Halstensen A; Lehmann AK; Guttormsen HK; Vollset SE; Bjune G; Naess A
    NIPH Ann; 1991 Dec; 14(2):157-65; discussion 166-7. PubMed ID: 1812430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine.
    Nøkleby H
    Expert Rev Vaccines; 2007 Oct; 6(5):863-9. PubMed ID: 17931164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a meningococcal vaccine.
    Poolman JT
    Infect Agents Dis; 1995 Mar; 4(1):13-28. PubMed ID: 7728353
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis.
    Keiser PB; Miller LB; Biggs-Cicatelli S; Zollinger WD
    Vaccine; 2009 Nov; 27(49):6809-13. PubMed ID: 19761833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982.
    Frøholm LO; Berdal BP; Bøvre K; Gaustad P; Harboe A; Holten E; Høiby EA; Lystad A; Omland T; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):133-8. PubMed ID: 6427703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polysaccharides and membrane vaccines.
    Poolman JT
    Adv Biotechnol Processes; 1990; 13():57-86. PubMed ID: 1970737
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.
    Walter EB; Moggio MV; Drucker RP; Wilfert CM
    Pediatr Infect Dis J; 1990 Sep; 9(9):632-5. PubMed ID: 2235187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults.
    Bulkow LR; McMahon BJ; Wainwright RB; Parkinson AJ; Wainwright KY; House J
    Arctic Med Res; 1993 Jul; 52(3):118-26. PubMed ID: 8397580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine.
    Rosenqvist E; Tjade T; Frøholm LO; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):139-49. PubMed ID: 6427704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meningococcal vaccines.
    Bethell D; Pollard AJ
    Expert Rev Vaccines; 2002 Jun; 1(1):75-84. PubMed ID: 12908514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The status of vaccines to meningococcal and gonococcal disease.
    Gotschlich EC
    Ann Inst Pasteur Microbiol (1985); 1985; 136B(3):341-55. PubMed ID: 2870677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Herd immunity" and the meningococcal vaccine trial in Norway.
    Bjune G
    Lancet; 1992 Aug; 340(8814):315. PubMed ID: 1353236
    [No Abstract]   [Full Text] [Related]  

  • 38. Physical and chemical parameters for the characterisation of the group C polysaccharide of the Cuban meningococcal BC vaccine.
    Martinez-Cabrera I; Muñoz Y; Fajardo EM; Jones C; Lemercinier X; Crane D; Cuevas M; Duarte M; Moreira T; Campa C; Abreu J
    Dev Biol (Basel); 2000; 103():267-8. PubMed ID: 11214248
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.
    Fries LF; Montemarano AD; Mallett CP; Taylor DN; Hale TL; Lowell GH
    Infect Immun; 2001 Jul; 69(7):4545-53. PubMed ID: 11401998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991.
    Aavitsland P; Bjune G; Aasen S; Halvorsen S
    NIPH Ann; 1991 Dec; 14(2):133-4; discussion 136-7. PubMed ID: 1812426
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.